Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024

Description

EXECUTIVE SUMMARY

The first transplant using cord blood-derived hematopoietic stem cells (HSCs) occurred in October 1988. Since then, significant advancements have been made in researching umbilical cord blood-derived hematopoietic and progenitor cells. To date, over 40,000 umbilical cord blood transplants (UCBTs) have been performed worldwide, treating a variety of conditions, including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. Public cord blood banks now store more than 800,000 units, while private banks house over 8.1 million units globally.

Cord blood storage began as a commercial service in the early 1990s, but cord tissue storage only became available commercially in 2008, with HealthBanks Biotech Company Ltd. in Taiwan leading the way. Hong Kong's HealthBaby and Cryolife also introduced the service in 2009. In the U.S., Cord Blood Registry (CBR) was the first private company to offer cord tissue storage in July 2010. Today, nearly all U.S. cord blood banks and about one-third of global cord blood banks provide cord tissue storage.

LifebankUSA pioneered placental blood storage in the U.S. in 2006 and introduced placental tissue storage in 2011. Americord Registry followed with placental tissue banking in September 2017. Internationally, several cord blood banks now offer placental blood and tissue storage. Some have diversified into other stem cell sources, such as dental pulp stem cells. For example, DentCell, managed by Cryoholdco, Latin America's largest cord blood banking consolidator, focuses on dental pulp stem cells. Additionally, a few cord blood banks are expanding into adipose-derived stem cell storage.

Recent years have seen record levels of merger and acquisition (M&A) activity in the cord blood industry. The market is now predominantly controlled by a handful of large cord blood banking operators, including Global Cord Blood Corporation (GCBC), Cord Blood Registry (owned by CooperSurgical), ViaCord, Cryo-Cell International, Cordlife Group, VCANBIO Cell & Gene Engineering Corporation, Lifecell International, Cryoholdco, and Medipost. This consolidation is notable given the rapid growth of the industry in the early 2000s. Significant consolidation has occurred in the U.S., Europe, Asia, and Latin America:

PBK FamiCord has acquired most of the European market, including merging with it largest competitor Vita34 and acquiring assets from Cryo-Save AG's 2019 bankruptcy.
CooperSurgical has consolidated reproductive, newborn stem cell, and genetic services within the U.S., managing at least 1.1 million units.
Cryoholdco has amassed stem cell banking assets across Latin America, including four in Mexico, two in Colombia, two in Brazil, and one in Peru, totaling an estimated 300,000 units.
Sanpower Group dominates the Asian market through its ownership of Global Cord Blood Corporation and other assets across Southeast Asia, controlling over 1.2 million units.
India, with its burgeoning population of 1.4 billion, rivals China in size, making up approximately 36% of the world's 7.8 billion people. LifeCell International is the leading stem cell bank in India, storing over 320,000 units.

The cord blood industry has also seen substantial advancements in perinatal tissue applications, including umbilical cord blood, umbilical cord tissue, placental blood and tissue, and amniotic fluid. This has led to a proliferation of storage services for these biomaterials.

Many cord blood banks have expanded their offerings to include:

Reproductive and assisted fertility services
Pre-and post-natal genetic testing
Cell therapy product development

The Cord Blood and Tissue Market is composed of several segments, including:

1. Storage (Cryopreservation): Revenue comes from cord blood collection, processing, and long-term storage contracts. Investment firms have recently entered this market, acquiring stakes in cord blood and tissue banks.
2. Transplantation Medicine: There is a robust market for cord blood use in treating diseases such as leukemia and sickle cell disease. Over 40,000 UCB transplants have been performed, with more than 80 medical conditions approved for treatment with cord blood-derived stem cells.
3. Regenerative Medicine: Research into the use of cord blood and tissue in regenerative medicine is expanding. Clinical trials are exploring treatments for neurological disorders like cerebral palsy, autism spectrum disorder, and hearing loss. RheinCell Therapeutics, now owned by Catalent, has achieved GMP certification for manufacturing cord blood-derived iPSCs. The FDA approved the world's first expanded cord blood cell therapy, Omisirge, in April 2023.
4. Research Supply Products: This segment includes cells, tissues, reagents, and kits. Major market leaders such as Lonza, STEMCELL Technologies, and AllCells are now offering cord blood products for research purposes.

This report provides a comprehensive analysis, including:

1. The number of cord blood and tissue units cryopreserved in public and private banks worldwide.
2. The number of hematopoietic stem cell transplants performed globally using cord blood cells.
3. The use of cord blood cells in regenerative medicine clinical trials.
4. The decline in cord blood utilization for HSCT since 2005.
5. Emerging technologies influencing public cord blood banks' financial sustainability.
6. Future prospects for companion products derived from cord blood.
7. The evolving landscape of the cord blood and tissue banking market.
8. Expansion and extension of services by cord blood banks.
9. Economic models and cost analyses for public and private cord blood banks.
10. Profit margins and pricing for processing and storage in private banks.
11. Rates per cord blood unit in the U.S. and Europe.
12. Indications for cord blood-derived HSCs in transplantation medicine.
13. Diseases targeted by cord blood-derived MSCs in regenerative medicine.
14. Cord blood processing technologies and the dominant market leaders offering them.
15. Clinical trials, published scientific papers, and funding for cord blood research.
16. Patents for cord blood, cord tissue, and placental products.
17. Transplantation data from various cord blood registries.

Key questions addressed in this market report include:

1. Strategies to improve the financial stability of private cord blood banks.
2. Strategies to improve the financial stability of public cord blood banks.
3. Companion products being developed from cord blood and tissue.
4. Costs for processing and storing cord blood.
5. Market value of cryopreserved cord blood units upon release.
6. Financial losses commonly incurred by public cord blood banks.
7. Net profit margins for private cord blood banks.
8. Pricing for processing and storage services in private banks.
9. Rates per cord blood unit in the U.S. and Europe.
10. Revenues from cord blood sales for major banks.
11. Accreditation systems for cord blood and tissue banks.
12. Comparative merits of cord blood processing technologies.
13. Strategies to increase cord blood utilization in transplantation.
14. Preferred TNC counts for transplantation.
15. Number of registered clinical trials using cord blood and cord tissue.
16. Clinical trials studying ex vivo expansion of cord blood and a recent product approval.
17. Annual number of matching and mismatching cord blood transplantations.
18. Share of cord blood transplants compared to bone marrow and peripheral blood transplants.
19. Likelihood of finding matching allogeneic cord blood units by ethnicity.
20. Top countries for cord blood donations.
21. Diseases targeted by cord blood and tissue-derived MSCs in clinical trials.
22. Breakdown of clinical trials investigating cord blood-derived cells by geography, study type, phase, and funding.
23. Breakdown of trials exploring cord tissue-derived cells.
24. Current patent rates and leading jurisdictions for cord blood, cord tissue, and placental patents.
25. Leading inventors, applicants, and owners of perinatal stem cell patents.
26. Number of units stored by public and private banks worldwide.
27. Leading cord blood banks by region and storage volume.
28. Market sizes for cord blood and tissue banking and therapeutic applications.

This global strategic report offers a thorough analysis of the cord blood and tissue banking market, providing insights into current trends, future projections, and key players in the industry. It is an essential resource for those seeking a comprehensive understanding of the market without investing excessive time in research.

1. REPORT OVERVIEW

1.1. Statement of the Report
1.2. Executive Summary
1.3. Introduction

2. CORD BLOOD BANKS: AN OVERVIEW

2.1. Components of a Cord Blood Sample
2.2. Cord Blood Banks
- 2.2.1. Public Cord Blood Bank
  - 2.2.1.1. Public Cord Blood Banks in the U.S.
  - 2.2.1.2. Public Cord Blood Banks in Major European Countries
  - 2.2.1.3. Economic Model of Public Cord Blood Banks
  - 2.2.1.4. Cost Analysis for Public Cord Blood Banks
  - 2.2.1.5. Relationship between Costs and Release Rates
- 2.2.2. Private Cord Blood Banks
  - 2.2.2.1. Private Cord Blood Banks in the U.S
  - 2.2.2.2. Top Seven U.S. Private Cord Blood Banks by Size of Inventory
  - 2.2.2.3. Comparison of Top Three U.S. Private Cord Blood Banks
  - 2.2.2.4. Pricing for Processing and Storage of CB in Private Banks
  - 2.2.2.5. Major U.S. Private Cord Blood Banks by their Special Services
  - 2.2.2.6. Key Factors to be Considered by Parents before Choosing a Private Bank
  - 2.2.2.7. World's Top Ten Private Cord Blood Banks by Inventory
  - 2.2.2.8. Special Features of World's Largest Private Cord Blood Banks
  - 2.2.2.9. Cost Analysis for Private Cord Blood Banks
    - 2.2.2.9.1. Economic Model of Private Cord Blood Banks
    - 2.2.2.9.2. Profit Margins of Four Global Private Cord Blood Banks
- 2.2.3. Hybrid Cord Blood Banks
- 2.2.4. Cross-over Cord Blood Bank
- 2.2.5. Community Cord Blood Bank
2.3. Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.

3. CORD BLOOD BANK ACCREDITATIONS

3.1. American Association of Blood Banks (AABB)
- 3.1.1. AABB Accreditation Phases and Expectations
3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
- 3.2.1. FACT Standards
- 3.2.2. FACT Accreditation Process
3.3. FDA Registration of Cord Blood Banks
- 3.3.1. FDA Biologics License Application (BLA) for Cord Blood
- 3.3.2. Investigation New Drug (IND) for Cord Blood
3.4. Human Tissue Authority (HTA) in U.K.
3.5. Therapeutic Goods Act (TGA) in Australia
3.6. International NetCord Foundation

4. PATENT LANDSCAPE OF UMBILICALCORD BLOOD, CORD TISSUE & PLACENTA

4.1. Umbilical Cord Blood Stem Cell Patents
- 4.1.1. Legal Status of Cord Blood Patents
- 4.1.2. Umbilical Cord Blood Patent Applications by Year
- 4.1.3. Umbilical Cord Blood Patent Application by Jurisdiction
- 4.1.4. Top Ten Umbilical Cord Blood Patent Applicants
- 4.1.5. Top Ten Inventors of Umbilical Cord Blood Patents
- 4.1.6. Top Twenty Owners of Umbilical Cord Blood Patents
4.2. Patents on Umbilical Cord Blood-Derived MSCs
- 4.2.1. Legal Status of UCB-Derived MSC Patents
- 4.2.2. UCB-Derived MSC Patent Applications by Year
- 4.2.3. UCB-Derived MSC Patent Application by Jurisdiction
- 4.2.4. Top Ten UCB-Derived MSC Patent Applicants
- 4.2.5. Top Ten Inventors of UCB-Derived MSC Patents
- 4.2.6. Top Twenty Owners of UCB-Derived MSC Patents
4.3. Patents on Cord Tissue
- 4.3.1. Legal Status of Cord Tissue Patents
- 4.3.2. Cord Tissue Patent Applications by Year
- 4.3.3. Cord Tissue Patent Application by Jurisdiction
- 4.3.4. Top Ten Cord Tissue Patent Applicants
- 4.3.5. Top Ten Inventors of Cord Tissue Patents
- 4.3.6. Top Twenty Owners of Cord Tissue Patents
4.4. Patents on Placenta
- 4.4.1. Leading Placenta-based Patent Applicants
- 4.4.2. Placental Tissue Patent Applications by Year, 2000-2022
- 4.4.3. Top Ten Jurisdictions of Placental Tissue Patents
- 4.4.4. Top Ten Inventors of Placental Tissue Patents
- 4.4.5. Top Twenty Owners of Placental Tissue Patents
- 4.4.6. Legal Status of Placental Tissue Patents
4.5. Patents on Cord Blood Expansion
- 4.5.1. Number of Cord Blood Expansion Patent Applications by Year
- 4.5.2. Top Ten Jurisdictions of CB Expansion Patents
- 4.5.3. Legal Status of Cord Blood Expansion Patents
- 4.5.4. Top Ten Inventors of Cord Blood Expansion Patents
- 4.5.5. Top 20 Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

5.1. Number of Papers Published on Umbilical Cord Blood
5.2. Scientific Publications on Cord Tissue
5.3. Scientific Publications on Placental Tissue
5.4. Scientific Publications on UCB Cell Expansion

6. CLINICAL TRIAL: CORD BLOOD, CORD TISSUE, PLACENTA AND CB EXPANSION

6.1. Clinical Trials involving Cord Blood Stem Cells
- 6.1.1. Number of Clinical Trials using Cord Blood Stem Cells by Geography
- 6.1.2. Number of Cord Blood Clinical Trials by Study Type
- 6.1.3. Number of Clinical Trials by Phase of Study
- 6.1.4. Number of Clinical Trials by Funder Type
- 6.1.5. Diseases Addressed by Currently Recruiting Cord Blood Clinical Trials
- 6.1.6. Companies Participating in Cord Blood Clinical Trials
6.2. Clinical Trials Using Umbilical Cord Tissue
- 6.2.1. Number of Clinical Trials using Cord Tissue by Region
- 6.2.2. Number of Umbilical Cord Tissue Clinical Trials by Phase of Study
- 6.2.3. Number of Cord Tissue Clinical Trials by Funder Type
- 6.2.4. Commercial Entities in Umbilical Cord Tissue Clinical Trials
6.3. Clinical Trials using Placental Tissue Stem Cells
- 6.3.1. Number of Placental Tissue Clinical Trials by Phase of Study
6.4. Clinical Trials of Expanded Cord Blood
- 6.4.1. Major Participants in Clinical Trials using Expanded Cord Blood Cells

7. CORD BLOOD PROCESSING TECHNOLOGIES: AN OVERVIEW

7.1. The Process of Separation of Cord Blood Stem Cells
- 7.1.1. PrepaCyte CB
  - 7.1.1.1. Advantages of PrepaCyte-CB
  - 7.1.1.2. Treatment Outcomes with PrepaCyte-CB
- 7.1.2. Hetastarch (HES)
- 7.1.3. AutoXpress (AXP)
- 7.1.4. SEPAX
- 7.1.5. Plasma Depletion Method (MaxCell Process)
- 7.1.6. Density Gradient Method
7.2. Comparative Merits of Different Processing Methods
- 7.2.1. Early Stage HSC Recovery by Technologies
- 7.2.2. Mid Stage HSC (CD34+/CD133+) Recovery from CB by Technologies
- 7.2.3. Late Stage Recovery of HSC from Cord Blood by Technologies
- 7.2.4. HSC (CD45+) Recovery
7.3. Days to Neutrophil Engraftment by Technologies
7.4. Anticoagulants used in Cord Blood Processing
- 7.4.1. Type of Anticoagulant and Cell Recovery Volume
7.5. Percent Cell Recovery by Sample Size
7.6. TNC Viability by Time Taken for Transport and Type of Anticoagulant
7.7. Cryopreservation of Cord Blood Cells
- 7.7.1. Ideal Cryoprotectants
7.8. Bioprocessing of Umbilical Cord Tissue (UCT)
7.9. Cord Blood Expansion Technologies
- 7.9.1. Notch Ligand Delta 1
- 7.9.2. Co-Culture with MSCs
- 7.9.3. Copper Chelation
- 7.9.4. Nicotinamide
- 7.9.5. StemRegenin 1 (SR1)
- 7.9.6. UM171
- 7.9.7. Augmentation of Homing
- 7.9.8. Prostaglandin E2
- 7.9.9. Complement 3a (C3a)
- 7.9.10. Fucosylation

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

8.1. Number of Allogeneic CBU Donors and CBUs Available Worldwide
8.2. HLA Typing of Worldwide Unrelated CB Donors and CBUs in 2021
8.3. Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
8.4. Global Exchange of Cord HSCs

9. INDICATIONS FOR UMBILICAL CORD BLOOD TRANSPLANTATION

9.1. Beneficial Properties of Cord Blood Stem Cells
- 9.1.1. Hematopoietic Properties of UCBCs
- 9.1.2. Immune Properties of UCBCs
- 9.1.3. Impact of HLA mismatch in UCBT Recipients
9.2. Malignant Indications for UCB Transplantation
9.3. Non-Malignant Diseases Treated by UCB Transplantation
9.4. Diseases being Studied using UCB as Regenerative Medicine

10. CORD BLOOD: AS A TRANSPLANT MEDICINE

10.1. Numbers of CB, BM and PB Stem Cell Transplantations Compared
10.2. Cord Blood Stem Cells Transplantation by Geography, 1999-2021
- 10.2.1. Indications for Hematopoietic Stem Cell Transplants (HSCTs) in the U.S.
  - 10.2.1.1. Top Five Indications for HCT in the U.S.
  - 10.2.1.2. Trends in Allogeneic HCTs in the U.S., by Recipient Age
  - 10.2.1.3. Trends in the Autologous HCT in the U.S. by Recipient Age
  - 10.2.1.4. HCTs by Cell Source in Adult Patients in the U.S.
  - 10.2.1.5. HCTs by Cell Source in less than 18 Patients in the U.S.
  - 10.2.1.6. Trends in the Use of Cord Blood HCTs in Adult & less than 18 Patients in the U.S.
  - 10.2.1.7. Number of Allogeneic CB HCTs in the U.S. by Race
  - 10.2.1.8. Number of HCTs Performed in the U.S. by Cell Source and Donor Type
  - 10.2.1.9. Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
  - 10.2.1.10. Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
- 10.2.2. Ethnic Background and Cord Blood HLA Matching in the U.S.
- 10.2.3. Cost of Cord Blood Transplantation
- 10.2.4. Complications through 1-Year Post HCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

11.1. Autism
11.2. Cerebral Palsy
11.3. Alzheimer's Disease
11.4. Diabetes
11.5. Heart Diseases
11.6. Multiple Sclerosis
11.7. Stroke

12. MARKET ANALYSIS

12.1. Cord Blood Banking Services Market
- 12.1.1. Share of Cord Blood Banking Service Market Revenue by Geography
- 12.1.2. Public vs. Private Cord Blood Banking Service Market
- 12.1.3. Global Market Share for Cord Blood and Cord Tissue Servicing
12.2. Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue
- 12.2.1. Market Share for CB Transplantation and CB for Regenerative Medicine
- 12.2.2. Percent Share of Cord Blood & Cord Tissue Market by Indication
12.3. Global Market for Umbilical Cord Tissue (UCT)

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

13.1. AllCells
- 13.1.1. Research Use Only (RUO) Products
  - 13.1.1.1. Mobilized Leukopak
  - 13.1.1.2. Leukopak
  - 13.1.1.3. Bone Marrow
  - 13.1.1.4. Cord Blood
  - 13.1.1.5. Whole Blood
- 13.1.2. GMP Products
  - 13.1.2.1. Clinical Grade Mobilized Leukopak
  - 13.1.2.2. Clinical Grade Leukopak
  - 13.1.2.3. Clinical Grade Bone Marrow
- 13.1.3. Isolated Cell Products
  - 13.1.3.1. CD34+ HSPCs
  - 13.1.3.2. T Cells
  - 13.1.3.3. NK Cells
  - 13.1.3.4. Monocytes
  - 13.1.3.5. B Cells
  - 13.1.3.6. PBMCs (MNCs)
13.2. AlphaCord
- 13.2.1. Prices
13.3. Americord Registry, Inc.
- 13.3.1. Cord Blood 2.0
- 13.3.2. Cord Tissue with CryoMax Processing
- 13.3.3. Placental Tissue with CryoMax processing
13.4. Angiocrine Bioscience
- 13.4.1. Proprietary E-CEL Platform
13.5. Anja Health Personalized Cord Blood Banking
13.6. Anthony Nolan
- 13.6.1. Anthony Nolan Grant
13.7. Baylx, Inc.
- 13.7.1. Product Pipeline
13.8. Be The Match
- 13.8.1. Hub of Transplant Network
- 13.8.2. Partners of Be The Match
- 13.8.3. Allogeneic Cell Sources in Be The Match Registry
- 13.8.4. Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
- 13.8.5. Growth of Cord Blood Units on Be The Match Registry
- 13.8.6. Diversity of CBUs in Be The Match Registry
13.9. Biocell Center
13.10. BioEden
- 13.10.1. Dental Pulp Cells
- 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
13.11. BioIntegrate, LLC
13.12. Bloodworks Northwest
- 13.12.1. Products & Services
13.13. California Umbilical Cord Collection Program
- 13.13.1. Participating Locations
13.14. Carolinas Cord Blood Bank (CCBB)
13.15. Celaid Therapeutics
- 13.15.1. In Vitro Expansion Technology
- 13.15.2. Business Model
13.16. Celebration Stem Cell Centre (CSCC)
- 13.16.1. Products
13.17. Cell Care
13.18. Cellenkos, Inc.
- 13.18.1. Technology
- 13.18.2. Cellenkos' Pipeline
13.19. Cells4Life Group LLP
- 13.19.1. Cellsplus
- 13.19.2. TotiCyte Processing Technology
- 13.19.3. Cord Blood Releases from Cells4Life
13.20. CellSave Arabia
- 13.20.1. Cord Blood Stem Cell Banking Services
- 13.20.2. Stem Cell Banking Price
13.21. Celularity, Inc.
13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
13.23. CHOC Blood Bank
13.24. Cleveland Cord Blood Center
- 13.24.1. Research on Diabetic Retinopathy
- 13.24.2. Research on Type I Diabetes
- 13.24.3. Research on Parkinson's disease
- 13.24.4. Research on Wound Healing
13.25. ClinImmune Cell and Gene Therapy
- 13.25.1. FDA Licensed Cord Blood
- 13.25.2. Gene Therapy
- 13.25.3. Cellular Therapies
13.26. Cord Blood Bank of Arkansas (CBBA)
13.27. Cord Blood Center Group
- 13.27.1. Cord Blood Units Released form Cord Blood Center Group
13.28. Cord Blood Registry (CBR)
- 13.28.1. Business Experience
- 13.28.2. Licensing & Accreditation
- 13.28.3. Pricing
13.29. Cord for Life
- 13.29.1. Technology: PremierMax
13.30. CordLife Group, Ltd.
- 13.30.1. Accreditations & Certifications
- 13.30.2. Services
- 13.30.3. Releases from CordLife
- 13.30.4. Revenue Generation by CordLife Group
13.31. CordVida
13.32. Crioestaminal
- 13.32.1. Cord Blood Transplantation in Portugal
13.33. Cryo-Cell International, Inc.
- 13.33.1. Processing Technology
- 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
- 13.33.3. Cryo-Cell International's Revenue Generation
- 13.33.4. Cryo-Cell International's Pricing
13.34. CryoCyte, LLC
13.35. CryoHoldco LATAM
13.36. Cryopoint
13.37. Cryoviva Biotech Pvt., Ltd.
13.38. DKMS gGMBH
- 13.38.1. Cord Blood Units
- 13.38.2. Services
- 13.38.3. DKMS' Donor Typing Profile & Active Donors
13.39. Duke University School of Medicine
- 13.39.1. Ducord (HPC Cord Blood)
13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
- 13.40.1. EBMT Transplant Activity
13.41. Ever Supreme Bio Technology, Co., Ltd.
- 13.41.1. Allogeneic UMSC01
- 13.41.2. New Research
13.42. ExCellThera
- 13.42.1. ECT-001 Cell Therapy
13.43. FamiCord Group
13.44. Fate Therapeutics, Inc.
- 13.44.1. FT1050 - Stem Cell Modulator
13.45. Future Health
- 13.45.1. Locations of Laboratories
- 13.45.2. Business Experience
- 13.45.3. Collection Kit
- 13.45.4. Transportation Container
- 13.45.5. Processing Method
- 13.45.6. Components Stored
- 13.45.7. Storage Methods
- 13.45.8. Licensing & Accreditation
- 13.45.9. Prices
- 13.45.10. Additional Services
13.46. Gamida Cell
- 13.46.1. OMIDUBICELL
13.47. GeneCell
13.48. Global Cord Blood Corporation (GCBC)
- 13.48.1. GCBC's Revenue Generation
13.49. Glycostem Therapeutics
- 13.49.1. Science and Technology
- 13.49.2. oNKord
- 13.49.3. viveNK
- 13.49.4. uNiK Production Process
13.50. Hawaii Cord Blood Bank
13.51. HealthBaby
- 13.51.1. Service Plans
- 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
- 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
- 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
13.52. HealthBanksUSA
- 13.52.1. BioArchive Cryogenic Storage System
- 13.52.2. AXP Cord Blood Processing
13.53. HEMAFUND
13.54. Hemogenyx Pharmaceuticals
- 13.54.1. Technology
13.55. IMMUNIQUE
13.56. Insception LifeBank
- 13.56.1. Cord Blood Releases from Insception LifeBank
- 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
13.57. JP McCarthy Cord Stem Cell Bank
13.58. Kangstem Biotech, Co., Ltd.
- 13.58.1. GD11 Brand
- 13.58.2. Core Technology
13.59. LifebankUSA
13.60. LifeCell International Pvt. Ltd.
13.61. Life Line Stem Cell
13.62. LifeSouth Cord Blood Bank
- 13.62.1. Accreditation & Hospital Partners
13.63. Magenta Therapeutics
- 13.63.1. Magenta's Cord Blood-Based Clinical Trial
13.64. Maze Cord Blood
13.65. Medipost, Co., Ltd.
- 13.65.1. Medipost's Product & Products in Development
  - 13.65.1.1. CARTISTEM
  - 13.65.1.2. PNEUMOSTEM
  - 13.65.1.3. SMUP-IA-01
13.66. Mesoblast, Ltd.
13.67. MD Anderson Cord Blood Bank
13.68. Mesoblast, Ltd.
- 13.68.1. Mesoblast's UCB-Based Clinical Trial
13.69. MiracleCord, Inc.
- 13.69.1. AXP II Automated Processing
- 13.69.2. StemCare Collection Kit
- 13.69.3. Cost of Cord Blood Banking
13.70. Mononuclear Therapeutics, Ltd.
- 13.70.1. MonoTx Cord Blood Bank
- 13.70.2. MonoTx's Pipeline
- 13.70.3. Products
  - 13.70.3.1. Human Cord Blood Mononuclear Cells (MNCs)
  - 13.70.3.2. Exosome Rich Plasma (ERP)
  - 13.70.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
13.71. New England Cord Blood Bank, Inc.
- 13.71.1. Cord Blood Processing
- 13.71.2. Cord Blood & Tissue Storage
13.72. New York Blood Center
- 13.72.1. Blood Products & Services
- 13.72.2. Cell Therapies
- 13.72.3. Cord Blood
13.73. OrganaBio
- 13.73.1. OrganaBio's Proprietary Supply Chains
- 13.73.2. Perenatal Tissues
13.74. PacifiCord
- 13.74.1. FDA-Approved Sterile Collection Bags
- 13.74.2. AXP Processing System
- 13.74.3. BioArchive System
13.75. Plasticell Ltd.
- 13.75.1. CombiCult Technology
- 13.75.2. Hematopoietic Stem Cell Expansion
13.76. ReeLabs Pvt. Ltd.
13.77. Restem, LLC
- 13.77.1. Clinical Trial for COVID-19
- 13.77.2. Clinical Trial for Muscular Dystrophy
- 13.77.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
- 13.77.4. Clinical Trial for Heart Failure
13.78. San Diego Cord Blood Bank
13.79. Saneron CCEL Therapeutics, Inc.
- 13.79.1. U-CORD-CELL Program
- 13.79.2. SERT-CELL Program
13.80. SmartCells
13.81. SSM Cardinal Glennon Children's Medical Center
- 13.81.1. ALLOCORD
13.82. Stembanc, Inc.
- 13.82.1. Popular Packages from Stembanc
13.83. Stem Cell Cryobank, Inc.
13.84. StemCyte, Inc.
- 13.84.1. Services
- 13.84.2. Add On Services
- 13.84.3. StemCyte in Clinical Trials
- 13.84.4. StemCyte's Plans & Pricing
13.85. Throne Biotechnologies, Inc.
- 13.85.1. Effects of CB-SCs in Diabetics
- 13.85.2. Effects of CB-SCs on Alopecia Areata
13.86. Transcell Biolife
- 13.86.1. ScellCare
- 13.86.2. ToothScell
13.87. Upstate Cord Blood Bank
13.88. ViaCord
- 13.88.1. ViaCord's Complete Services
- 13.88.2. Cord Blood + Tissue Banking
- 13.88.3. Newborn Digestive Health
- 13.88.4. Newborn DNA Guardian
13.89. Versity, Inc.
13.90. Vita 34 AG
- 13.90.1. Revenue Generation by Vita 34 AG
13.91. Vitalant Clinical Services
- 13.91.1. Hospital Services
- 13.91.2. Laboratory Services
- 13.91.3. Research
13.92. World Marrow Donor Association (WMDA)
- 13.92.1. WMDA Search & Match Service
13.93. Worldwide Network for Blood & Marrow Transplantation (WBMT)

INDEX OF FIGURES

FIGURE 2.1: Parts of an Umbilical Cord
FIGURE 2.2: Percent Utilizations of BM-HSCs, PB-HSCs and CB-HSCs in Transplantations
FIGURE 2.3: Components of a Cord Blood Sample
FIGURE 2.4: Top Seven U.S. Private Cord Blood Banks by Size of Inventory
FIGURE 2.5: Cord Blood Revenues for Four Major Private Banks, 2017 to Present
FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks in the U.S.
FIGURE 2.7: % Share of Parents Storing CBUs in Private/Public Banks by Country/Region
FIGURE 4.1: Legal Status of Cord Blood Patents
FIGURE 4.2: Umbilical Cord Blood Patent Applications by Year, 2000 to Present
FIGURE 4.3: Umbilical Cord Blood Patent Application by Jurisdiction
FIGURE 4.4: Legal Status of Cord Blood Patents
FIGURE 4.5: UCB-Derived MSC Patent Applications by Year, 2000 to Present
FIGURE 4.6: UCB-Derived MSC Patent Application by Jurisdiction
FIGURE 4.7: Legal Status of Cord Tissue Patents
FIGURE 4.8: Umbilical Cord Patent Applications by Year, 2000 to Present
FIGURE 4.9: Placental Tissue
FIGURE 4.10: Placental Tissue Patent Applications by Year, 2000 to Present
FIGURE 4.11: Number of Cord Blood Expansion Patent Applications, 2000 to Present
FIGURE 5.1: Number of Published Papers on UCB according to PubMed.gov, 2000 to Present..
FIGURE 5.2: Number of Publications on Umbilical Cord Tissue, 2000 to Present
FIGURE 5.3: Number of Publications on Placental Tissue
FIGURE 5.4: Number of Scientific Publications on UCB Cell Expansion, 2000 to Present
FIGURE 6.1: Number of Cord Blood Clinical Trials by Geography
FIGURE 6.2: Number of Cord Blood Clinical Trials by Study Type
FIGURE 6.3: Number of Cord Blood Clinical Trials by Phase of Study
FIGURE 6.4: Number of Cord Blood Clinical Trials by Funder Type
FIGURE 6.5: Major Indications Addressed by Currently Recruiting Clinical Trials
FIGURE 6.6: Number of Clinical Trials using Cord Tissue by Region/Country
FIGURE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
FIGURE 6.8: Number of Cord Blood Clinical Trials by Funder Type
FIGURE 7.1: Separation of Buffy Layer
FIGURE 7.2: PrepaCyte-CB
FIGURE 7.3: Hetastarch (HES)
FIGURE 7.4: AutoXpress II
FIGURE 7.5: SEPAX 2
FIGURE 7.6: Plasma Depletion (PD) Method (MaxCell Process)
FIGURE 7.7: Density Gradient Separation of Cord Blood
FIGURE 7.8: Early Stage HSC Recovery from Cord Blood by Technologies
FIGURE 7.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
FIGURE 7.10: Late Stage Recovery of HSC from Cord Blood by Technologies
FIGURE 7.11: HSC (CD45+) Recovery Post Process from CB by Technologies
FIGURE 7.12: Days to Neutrophil Engraftment by Technologies
FIGURE 7.13: Differences in TNC Recovery among Anticoagulants
FIGURE 7.14: Type of Anticoagulant and Cell Recovery Volume
FIGURE 7.15: Percent Cell Recovery by Sample Size
FIGURE 7.16: TNC Viability by Time Taken for Transport
FIGURE 7.17: Difference in Recovery of VIABLE TNC after Thawing
FIGURE 7.18: CD34+ Cell Count CFU and Cell Apoptosis by Cryoprotectants
FIGURE 8.1: HLA Typing of Worldwide Unrelated CB Donors and CBUs
FIGURE 8.2: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
FIGURE 8.3: Global Exchange of Cord HSCs
FIGURE 9.1: Percent Utilization of PB, BM and CB in Transplantations Worldwide
FIGURE 10.1: CB, BM and PB Stem Cell Transplantations Compared, 1997-2021
FIGURE 10.2: Cord Blood Stem Cells Transplantation by Geography, 1999 to Present
FIGURE 10.3: Major Five Indications for HCT in the U.S.
FIGURE 10.4: Trends in Allogeneic HCTs in the U.S., by Recipient Age
FIGURE 10.5: Trends in the Autologous HCT in the U.S. by Recipient Age
FIGURE 10.6: HCTs by Cell Source in Adult Patients in the U.S.
FIGURE 10.7: HCTs by Cell Source in less than 18 Patients in the U.S.
FIGURE 10.8: Trends in the Use of CB HCTs in greater than or equal to 18 & less than 18 Patients in the U.S.
FIGURE 10.9: Number of Allogeneic CB HCTs in the U.S. by Race
FIGURE 10.10: Use of CB Allogeneic HCTs in the U.S. in Recipients Aged less than 18 Years
FIGURE 10.11: Use of Allogeneic CB HCTs in the U.S. in Recipients Aged greater than or equal to 18 Years
FIGURE 12.1: Global Cord Blood Banking Service Market, 2022-2030
FIGURE 12.2: % Share of Cord Blood Banking Service Market Revenue by Geography
FIGURE 12.3: Global Cord Blood Banking Service Market, Public vs. Private
FIGURE 12.4: Global CB Banking Service Market Share for Cord Blood and Cord Tissue
FIGURE 12.5: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
FIGURE 12.6: Use of Umbilical Cord Blood in Transplantation vs. Regenerative Medicine
FIGURE 12.7: Percent Share of Umbilical Cord Blood and Tissue Utilization by Indication
FIGURE 13.1: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
FIGURE 13.2: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
FIGURE 13.3: Growth of CBUs on Be The Match Registry, 2001 to Present
FIGURE 13.4: Diversity of CBUs in Be The Match Registry
FIGURE 13.5: Funders for CIBMTR in 2022
FIGURE 13.6: Sales Revenues and Gross Profits for CordLife, 2014-2021
FIGURE 13.7: Cryo-Cell International's Revenue Generation, 2017-2022
FIGURE 13.8: GCBC's Revenue Generation, 2015-2022
FIGURE 13.9: Revenue Generation by Vita 34 AG, 2014-2021

INDEX OF TABLES

TABLE 2.1: An Overview of Public Cord Blood Banks
TABLE 2.2: Public Cord Blood Banks in the U.S.
TABLE 2.3: Public Cord Blood Banks in Major European Countries
TABLE 2.4: International Prices of a Cord Blood Unit (CBU)
TABLE 2.5: Prices of CBUs in National Marrow Donor Program (NMDP) Banks in the U.S.
TABLE 2.6: An Overview of Private Cord Blood Banks
TABLE 2.7: The Leading Private Cord Blood Banks in the U.S.
TABLE 2.9: Pricing for Storage in Commercial Cord Blood Banks
TABLE 2.10: Leading Private CB Banks by their Inventory Size and Geographic Location
TABLE 2.11: World's Largest Private Cord Blood Bank Operators by Inventory
TABLE 2.12: Cord Blood Revenues for Four Major Private Banks - 2017 to Present
TABLE 2.13: Comparison of Public, Private and Hybrid Cord Blood Banks
TABLE 3.1: AABB-Accredited Cord Blood Banks
TABLE 3.2: Select FACT-Accredited Cord Blood Banks
TABLE 4.1: Umbilical Cord Blood Patent Application by Jurisdiction
TABLE 4.2: Top Ten Umbilical Cord Blood Patent Applicants
TABLE 4.3: Top Ten Inventors of Umbilical Cord Blood Patents
TABLE 4.4: Top Twenty Owners of Umbilical Cord Blood Patents
TABLE 4.5: UCB-Derived MSC Patent Applications by Jurisdiction
TABLE 4.6: Top Ten UCB-Derived MSC Patent Applicants
TABLE 4.7: Top Ten Inventors of UCB-Derived MSC Patents
TABLE 4.8: Top Twenty Owners of UCB-Derived MSC Patents
TABLE 4.9: Cord Tissue Patent Application by Jurisdiction
TABLE 4.10: Top Ten Wharton's Jelly Patent Applicants
TABLE 4.11: Top Ten Inventors of Cord Tissue Patents
TABLE 4.12: Top Twenty Owners of Cord Tissue Patents
TABLE 4.13: Top Ten Applicants of Placental Tissue Patents
TABLE 4.14: Top Ten Jurisdictions of Placental Tissue Patents
TABLE 4.15: Top Ten Inventors of Placental Tissue Patents
TABLE 4.16: Top Twenty Owners of Placental Tissue Patents
TABLE 4.17: Legal Status of Placental Tissue Patents
TABLE 4.18: Top Ten Jurisdictions of CB Expansion Patents
TABLE 4.19: Legal Status of Cord Blood Expansion Patents
TABLE 4.20: Top Ten Inventors of Cord Blood Expansion Patents
TABLE 4.21: Top Twenty Owners of Placental Tissue Patents
TABLE 6.1: Total Number of Umbilical Cord-Related Clinical Studies
TABLE 6.2: Number of Cord Blood Clinical Trials by Geography
TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type
TABLE 6.4: Number of Cord Blood Clinical Trials by Phase of Study
TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type
TABLE 6.6: List of Select Companies Participating in Cord Blood Clinical Trials
TABLE 6.7: Number of Cord Tissue Clinical Trials by Phase of Study
TABLE 6.8: Number of Cord Tissue Clinical Trials by Funder Type
TABLE 6.9: Select Commercial Entities in Umbilical Cord Tissue Clinical Trials
TABLE 6.10: Number of Placental Tissue Clinical Trials by Phase of Study
TABLE 6.11: Major Industry Participants using Expanded Cord Blood in Clinical Trials
TABLE 7.1: Advantages of PrepaCyte-CB
TABLE 7.2: Treatment Outcomes with PrepaCyte-CB
TABLE 7.3: Cord Blood Expansion Approaches in Ongoing Clinical Trials
TABLE 8.1: Cord Blood Units Registered with WMDA Registry
TABLE 8.2: Number of Unrelated CB Donors and CBUs available Worldwide
TABLE 8.3: Unrelated BM, PB and CB Hematopoietic Stem Cell Units Shipped Worldwide
TABLE 9.1: Malignant Diseases Treated by UCB Transplantation
TABLE 9.2: Non-Malignant Diseases Treated by UCB Transplantation
TABLE 9.3: Diseases being studied using UCB as Regenerative Medicine
TABLE 10.1: Numbers of CB, BM and PB Stem Cell Transplantations Compared by Year
TABLE 10.2: Number of HCTs Performed in the U.S. by Disease as reported to CIBMTR
TABLE 10.3: Number of HCTs Performed in the U.S. by Cell Source and Donor Type
TABLE 10.4: Comparison of Median Costs during Transplant Admit
TABLE 10.5: Complications Post HCT in UCB vs. MRD BM/PBSC vs. MURD BM/PBSC
TABLE 11.1: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Autism
TABLE 11.2: Trials Evaluating the Effect of Cord Blood Stem Cells on Cerebral Palsy
TABLE 11.3: Clinical Trials Studying the Effect of CBU on Alzheimer's Disease
TABLE 11.4: Clinical Trials Evaluating the Effect of Cord Blood Stem Cells on Diabetes
TABLE 11.5: Trials Evaluating the Effect of Cord Blood Stem Cells on Heart Diseases
TABLE 11.6: Clinical Trials Evaluating the Effect of UCB on Multiple Sclerosis
TABLE 11.7: Clinical Trials Evaluating the Effect of UCB on Stroke
TABLE 12.1: Global Cord Blood Banking Service Market, 2022-2030
TABLE 12.2: Global Market for Therapeutic Applications of Umbilical Cord Blood & Tissue, 2022-2030
TABLE 13.1: Angiocrine's R&D Pipeline
TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
TABLE 13.3: Growth of Cord Blood Units in Be The Match Registry by Year
TABLE 13.4: Diversity of CBUs in Be The Match Registry
TABLE 13.5: Cell Care's Pricing for Cord Blood Processing and Storage
TABLE 13.6: Cellenkos' Product Pipeline
TABLE 13.7: Cord Blood Releases from Cells4Life
TABLE 13.8: Celularity's Active Clinical Pipeline
TABLE 13.9: Cord Blood Unitts Released from Cord Blood Center Group by Year
TABLE 13.10: Cord Blood and Cord Tissue Units Released from CordLife
TABLE 13.11: Recovery of Viable CFU by PrepaCyte-CB
TABLE 13.12: Cryo-Cell International's Revenue Generation, 2017 to Present
TABLE 13.13: Cryo-Cell International's Pricing
TABLE 13.14: CryoCyte's Option Plans & Pricing
TABLE 13.15: DKMS' Donor Typing Profile & Active Donors
TABLE 13.16: Allogeneic and Autologous infusions by Indication Reported by EBMT
TABLE 13.17: Cord Blood Banking Cost in GeneCell
TABLE 13.18: GCBC's Revenue Generation, 2015 to Present
TABLE 13.19: Glycostem's Product Pipeline
TABLE 13.20: Insception LifeBank's Pricing
TABLE 13.21: Cord Blood Releases from Insception LifeBank for Transplantation
TABLE 13.22: Cord Blood Cells Released for Regenerative Medicine from Insception
TABLE 13.23: Kangstem's Sponsor Initiated Clinical Trials
TABLE 13.24: LifeCell International's Pricing
TABLE 13.25: Maze Cord Blood: Banking Cost
TABLE 13.26: MiracleCord's Cord Blood Banking Cost
TABLE 13.27: MonoTx's Product Pipeline